Changes in Hong Kong stocks | Dongyang Pharmaceutical (06887) rose nearly 7%, with a gross profit of 1,468 billion yuan in the medium term, ifenidone key data revealed at the US IPF Summit

The Zhitong Finance App learned that Dongyang Pharmaceutical (06887) rose nearly 7%. As of press release, it had risen 6.83% to HK$53.95, with a turnover of HK$20.6019 million.

According to the news, recently, Dongyang Pharmaceutical announced its 2025 interim results, with revenue of 1,938 billion yuan (RMB, same below); gross profit of 1,468 billion yuan. The announcement said that due to the slowdown in the influenza epidemic compared to the same period last year, the Group's oseltamivir phosphate products were affected to a certain extent, achieving a turnover of 1,301 billion yuan, but still maintaining a leading position in the industry.

It is worth mentioning that the 9th Idiopathic Pulmonary Fibrosis (IPF) Summit was held in Boston, USA from August 19 to 21, 2025. Dongyang Pharmaceutical appeared at this summit. Chief Scientist Dr. Lin Kai publicly disclosed key data from the phase II clinical trial of the innovative anti-fibrosis drug ifenidone (HEC585) under development for the first time on the main agenda of the conference.

According to reports, ifenidone unveiled at this summit is the first domestically produced IPF original drug developed by Dongyang Pharmaceutical to enter phase III clinical trials. At the same time, it can also expand diseases such as progressive fibrosis interstitial lung disease (PF-ILD), hepatitis B liver fibrosis, and interstitial pneumonia. By simultaneously inhibiting the release of TNF-α and TGF-β1 and blocking the TGF-β1-SMAD signaling pathway, the deposition of extracellular matrices such as collagen and progression of fibrosis are inhibited, and PI3K-AKT, MAPK, and HIPPO signaling pathways are regulated through targets such as NR4A1 and BMP2 to form a broad anti-fibrosis network to achieve therapeutic effects.